Pazopanib

Generic Name
Pazopanib
Brand Names
Votrient
Drug Type
Small Molecule
Chemical Formula
C21H23N7O2S
CAS Number
444731-52-6
Unique Ingredient Identifier
7RN5DR86CK
Background

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions
Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Associated Therapies
-
Clinical Trials
Related News

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Phase 2
Completed
Conditions
Chondrosarcoma
Metastatic Chondrosarcoma
Interventions
Drug: pazopanib
First Posted Date
2011-04-07
Last Posted Date
2023-03-10
Lead Sponsor
George Clinical Pty Ltd
Target Recruit Count
47
Registration Number
NCT01330966
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Edward Cancer Center, Naperville, Illinois, United States

and more 4 locations

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)

Phase 2
Completed
Conditions
GIST
Interventions
Drug: Pazopanib
Other: Best supportive care
First Posted Date
2011-03-25
Last Posted Date
2016-02-25
Lead Sponsor
Centre Leon Berard
Target Recruit Count
81
Registration Number
NCT01323400
Locations
🇫🇷

Hôpital Tenon, Paris, France

🇫🇷

Centre Oscar Lambret, Lille, France

🇫🇷

Hôpital St Antoine, Paris, France

and more 10 locations

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

Phase 2
Terminated
Conditions
Lung Cancer, Small Cell
Interventions
Drug: pazopanib
Drug: pemetrexed
First Posted Date
2011-03-14
Last Posted Date
2014-10-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
20
Registration Number
NCT01313663
Locations
🇺🇸

GSK Investigational Site, Vancouver, Washington, United States

Pazopanib as Single Agent in Advanced NETs

Phase 2
Completed
Conditions
Advanced/Metastatic Neuroendocrine Tumors
Interventions
Drug: Pazopanib
First Posted Date
2011-01-20
Last Posted Date
2019-05-29
Lead Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Target Recruit Count
44
Registration Number
NCT01280201
Locations
🇪🇸

Hospital Universitario Virgen de la Victoria, Málaga, Spain

🇪🇸

Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain

🇪🇸

Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 7 locations

Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer

Phase 2
Completed
Conditions
Platinum-resistant Advanced Ovarian Cancer
Interventions
Drug: Pazopanib
First Posted Date
2010-12-17
Last Posted Date
2016-08-11
Lead Sponsor
Grupo Español de Investigación en Cáncer de Ovario
Target Recruit Count
28
Registration Number
NCT01262014
Locations
🇪🇸

H. de la Santa Creu i Sant Pau, Barcelona, Spain

🇪🇸

H. Alcorcón, Alcorcón, Spain

🇪🇸

H Vall d'Hebron, Barcelona, Spain

and more 17 locations

Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

Phase 2
Completed
Conditions
Lung Cancer
Interventions
Drug: Pazopanib
First Posted Date
2010-12-17
Last Posted Date
2017-03-07
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
15
Registration Number
NCT01262820
Locations
🇺🇸

North Carolina Cancer Hospital at U of North Carolina at CH, Chapel Hill, North Carolina, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2
Completed
Conditions
Small Cell Lung Cancer
Lung Cancer
SCLC
Interventions
Drug: Pazopanib
First Posted Date
2010-12-03
Last Posted Date
2019-04-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
33
Registration Number
NCT01253369
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

Phase 1
Completed
Conditions
Epithelial Ovarian Cancer
Interventions
Drug: Pazopanib
First Posted Date
2010-11-11
Last Posted Date
2016-02-10
Lead Sponsor
Priv.-Doz. Dr. med. Joachim Rom
Target Recruit Count
10
Registration Number
NCT01238770
Locations
🇩🇪

Universitäts-Frauenklinik, Heidelberg, Germany

🇩🇪

Klinikum Konstanz Gynäkologie und Geburtshilfe, Konstanz, Germany

🇩🇪

Marienkrankenhaus Hamburg, Hamburg, Germany

and more 2 locations

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

First Posted Date
2010-11-07
Last Posted Date
2020-11-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
1538
Registration Number
NCT01235962
Locations
🇬🇧

Novartis Investigative Site, Wolverhampton, United Kingdom

Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women

Phase 2
Completed
Conditions
Neoplasms, Ovarian
Interventions
Drug: Placebo comparator
Drug: Pazopanib
First Posted Date
2010-10-25
Last Posted Date
2015-03-03
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
145
Registration Number
NCT01227928
Locations
🇨🇳

GSK Investigational Site, Taipei, Taiwan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy